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ABSTRACT
Chemotherapy-induced cognitive impairment (CICI) is now widely recognized
as a real and too common complication of cancer chemotherapy experienced by an
ever-growing number of cancer survivors. Previously, we reported that doxorubicin
(Dox), a prototypical reactive oxygen species (ROS)-producing anti-cancer drug,
results in oxidation of plasma proteins, including apolipoprotein A-I (ApoA-I) leading
to tumor necrosis factor-alpha (TNF-α)-mediated oxidative stress in plasma and brain.
We also reported that co-administration of the antioxidant drug, 2-mercaptoethane
sulfonate sodium (MESNA), prevents Dox-induced protein oxidation and subsequent
TNF-α elevation in plasma. In this study, we measured oxidative stress in both brain
and plasma of Dox-treated mice both with and without MESNA. MESNA ameliorated
Dox-induced oxidative protein damage in plasma, confirming our prior studies, and
in a new finding led to decreased oxidative stress in brain. This study also provides
further functional and biochemical evidence of the mechanisms of CICI. Using novel
object recognition (NOR), we demonstrated the Dox administration resulted in memory
deficits, an effect that was rescued by MESNA. Using hydrogen magnetic resonance
imaging spectroscopy (H1-MRS) techniques, we demonstrated that Dox administration
led to a dramatic decrease in choline-containing compounds assessed by (Cho)/creatine
ratios in the hippocampus in mice. To better elucidate a potential mechanism for this
MRS observation, we tested the activities of the phospholipase enzymes known to act
on phosphatidylcholine (PtdCho), a key component of phospholipid membranes and a
source of choline for the neurotransmitter, acetylcholine (ACh). The activities of both
phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D were
severely diminished following Dox administration. The activity of PC-PLC was preserved
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when MESNA was co-administered with Dox; however, PLD activity was not protected.
This study is the first to demonstrate the protective effects of MESNA on Dox-related
protein oxidation, cognitive decline, phosphocholine (PCho) levels, and PC-PLC activity
in brain and suggests novel potential therapeutic targets and strategies to mitigate CICI.

ApoA-I promotes cholesterol efflux as part of the high
density lipoprotein (HDL) complex. Additionally, ApoA-I
has been shown to suppress TNF-α in plasma [34–36].
Previous studies showed that, when oxidized, ApoA-I
loses this ability to suppress TNF-α release and may
exacerbate the problem [10].
However, ApoA-I oxidation and subsequent increased
TNF-α release is suppressed with co-administration of the
drug MESNA (2-mercaptoethane sulfonate sodium) in mice
[10]. The structure of MESNA contains a free sulfhydryl
group imparting much of its antioxidant properties by
affording it the ability to scavenge free radicals and lipidderived reactive aldehydes such as 4-hydroxynonenal
(HNE) and acrolein. MESNA is FDA approved for
prevention of hemorrhagic cystitis and routinely used with
Dox as part of multidrug chemotherapy regimens that
include ifosfamide or cyclophosphamide. MESNA does
not enter cells and therefore does not interfere with cancer
chemotherapy [37]. Treatment of mice with MESNA blocks
protein oxidation, including ApoA-I, in the plasma [10].
Modulating the location and production of chemotherapyinduced production of ROS may be paramount in decreasing
the unwanted toxicities associated with chemotherapy while
enhancing the cancer-killing effects [38].
The current study was undertaken to test the
hypothesis that MESNA would block Dox-induced, TNFα-mediated markers of brain damage, indexed by changes
in oxidative stress and magnetic resonance spectroscopy
(MRS) spectra in brain, with consequent improved
cognition.

INTRODUCTION
Chemotherapy-induced cognitive impairment
(CICI), often termed “chemobrain” by patients, is
increasingly recognized as a significant complication of
cancer chemotherapy [1–7]. CICI consists of impairments
in various aspects of memory and executive function
[8, 9]. Despite the increased attention this issue has
garnered from the clinical and research communities, the
mechanisms of the resulting cognitive impairment still are
poorly understood but are thought to include peripheral
toxic effects caused by the chemotherapy drugs leading
to downstream structural and functional changes in the
brain. These latter changes include neuroinflammatory
consequences and even changes in neurotransmitter
levels and function [10–13]. The main reasons for the
slowness to address CICI may include the complexity
of cancer and its treatments, especially by agents that
do not cross the blood-brain barrier (BBB). Moreover,
a hitherto lack of a scientific explanation for cognitive
consequences of chemotherapy has hampered progress.
A better understanding of the underlying mechanisms by
which CICI occurs is necessary to allow cancer survivors
to have a better quality of life by protecting non-targeted
tissues against undesired toxicities of anticancer drugs.
In the present studies, we used doxorubicin (Dox)
as a representative chemotherapeutic agent known to
produce reactive oxygen species (ROS) [14–16]. Dox is
an anthracycline antineoplastic agent commonly used in
multidrug chemotherapy regimens primarily to treat solid
tumors and leukemia. The cancer-killing effects of Dox
have been shown to involve three proposed mechanisms:
DNA intercalation, inhibition of topoisomerase II, and
production of ROS [16–22]. The quinone moiety present
in the Dox structure is capable of undergoing a oneelectron reduction to the semi-quinone [10, 23]. Through
the redox cycling of this structure back to the quinone
in vivo, the reactive superoxide free radical (O2-•) is
produced from molecular oxygen. In addition, previous
studies by our laboratories demonstrated that even though
neither Dox nor its primary metabolite crosses the BBB,
peripheral Dox treatment causes brain injury as evidenced
by increased oxidative stress, elevated levels of the proinflammatory cytokine, tumor necrosis factor-alpha
(TNF-α), and mitochondrial dysfunction [24–27].
Our
laboratory
and
others
previously
demonstrated Dox-induced oxidative stress in
plasma and damage to plasma proteins subsequently
leading to detrimental central nervous system
consequences [10, 24, 28–31]. Central to this paradigm
is apolipoprotein A-I (ApoA-I) [4, 10, 32, 33].
www.oncotarget.com

RESULTS
Dox administration results in increases in
oxidative stress markers in brain and plasma
We previously showed that, despite its inability
to cross the BBB, peripheral Dox administration led to
increased levels of TNF-α and oxidative stress in brain [10,
11, 24, 27, 39]. Here, we tested for indicators of oxidative
stress in brain and plasma of animals used in this study.
Test subjects were administered either saline, MESNA,
Dox, or Dox plus MESNA. Brain and blood samples
were collected 72 h post-Dox treatment, immediately
following cognitive or MRS studies. Protein carbonyl
and protein-bound HNE levels were used as a gauge of
damage to proteins and lipids, respectively. Significantly
higher levels of protein carbonyls and protein-bound HNE
in brain of Dox-treated animals compared to saline-treated
controls were observed (p < 0.01, Figure 1A and p < 0.01,
Figure 1C, respectively). MESNA protected the brain from
30325
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these oxidative damages (p < 0.01, p < 0.01). Plasma
results confirmed similarly increased protein carbonyl
and protein-bound HNE levels in Dox vs. saline treated
animals (p < 0.0001, Figure 1B and p < 0.001, Figure
1D, respectively). Both effects were ameliorated when
MESNA was administered with Dox (p < 0.01, p < 0.05).
These results are consistent with our previous findings
in plasma [10] and brain [11, 27] and consistent with the
notion that concomitant MESNA administration may be
able to reduce or prevent these consequences in brain.

and the possibility that MESNA protected brain function,
NOR was performed on animals in each of the previously
mentioned treatment groups (Figure 2A). NOR provides
a measure of cognitive function in rodent models by
assessing the preference for investigating a novel object
in a familiar environment. Preference for the novel object
indicates memory of a familiar object and learning through
the animal’s natural propensity to explore an unfamiliar
object. Novelty recognition is thought to require more
complex cognitive function [40, 41]. NOR employs both
hippocampus and frontal cortex, thought to be key brain
regions affected in CICI (“chemobrain”). Open field
testing was employed as a measure of locomotor activity
among treatment groups (Figure 2B).
Prior to treatment, animals assigned to each of the
treatment groups spent an average of 65–70% of total

Dox administration results in cognitive
impairment and decreased locomotor activity
In order to determine potential cognitive
consequences of Dox-induced oxidative stress in brain

Figure 1: Levels of protein carbonyl and protein-bound HNE are indicators of protein oxidation and lipid peroxidation,
respectively. Graphs (A–D) depict protein carbonyl and protein-bound HNE in brain and plasma of 2–3 month old, male B6C3 mice treated

with saline, MESNA, Dox (25 mg/kg), or Dox with MESNA. MESNA was administered at 160 mg/kg i.p. 15 min before DOX/Saline as
well as 3 h and 6 h after Dox/Saline. Brain and plasma samples were acquired post 72 h treatments. Protein carbonyl levels were significantly
increased in brain (A) (**P < 0.01) and plasma (B) (****P < 0.0001) of mice treated with Dox relative to saline. MESNA, co-administered
with Dox, ameliorated Dox-induced increases in protein carbonyl in both brain and plasma (**P < 0.01). Protein-bound HNE levels were
significantly elevated in brain (**P < 0.01) and plasma (***P < 0.001) of mice treated with Dox relative to saline. MESNA, co-administered
with Dox, significantly suppressed Dox-induced elevation in protein-bound HNE in both brain (**P < 0.01) and plasma (*P < 0.05). N =
10–13 per treatment group.
www.oncotarget.com
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exploration time investigating the novel object. At 24 h
post-treatment, each subject was re-acclimated to the
environment containing the two original familiar objects
followed by exposure to one familiar and one novel object.
There is no difference among each treatment groups at 24 h.
At 72 h post-treatment, the saline and MESNA
treatment groups maintained an average RI of
approximately 70, similar to previous performance.
Meanwhile, the Dox treatment group performed at a
significantly decreased mean RI of around 40, suggesting
no preference for the novel object, reflecting Dox-induced
memory impairment. The RI of Dox treated group at 72
h post-treatment was significantly lower than all three
other groups (Saline, MESNA and Dox+MESNA) at
72 h post-treatment (*P < 0.05), suggesting a delayed
memorydecline by Dox. That corresponded to the time
when oxidative stress parameters were significantly
elevated (Figure 1). The group that received MESNA
with Dox had a mean RI of approximately 60 at 72 h posttreatment, significantly higher than the 72 h Dox treated
group, indicating a protection of cognitive function by
rescuing the Dox-induced delayed memory impairment.
Dox treatment significantly decreased the locomotor
activity compared to MESNA control group at 24 h post
treatment (*P < 0.05). Dox resulted in a progressive
decline in locomotor activity, which reached statistical
significance by 72 h post-treatment in Figure 2B
(*P < 0.05). The similar decrease in total locomotor
activity of the Dox and Dox+MESNA groups (Figure
2B) suggests a selective effect of MESNA on attenuating

Dox-induced memory impairment, and eliminates activity
level as a potential confounding variable when comparing
cognitive function results between these two groups.

Dox administration results in changes to the
neurochemical profile in the hippocampus
determined by MRS
The involvement of the hippocampus in learning
and memory [40, 42–45] led us to pursue MRS scans
of the hippocampus in the murine chemotherapy
treatment groups studied. H1-MRS non-invasively
measures neurochemical aspects of the living brain.
The peaks observed in this spectrum (Figure 3A)
include N-acetylaspartate (NAA), Choline-containing
compounds (Cho), creatine (Cr), myo-inositol, glutamate
and glutamine, lipids, and lactate allowing quantification
of these and other metabolites in the living brain [46].
Quantification is generally achieved using ratios to other
species, commonly to Cr.
Unilateral and bilateral hippocampal H1-MRS
showed a slight, but significant, decrease in the NAA/Cr
ratio in the Dox treated group compared to saline controls
(p < 0.05, Figure 3B). A decrease in NAA/Cr is indicative
of decreased neuronal integrity. Strikingly, MRS scans
revealed, on average, a much larger six standard-deviation
decrease in Cho/Cr in Dox-treated mice compared to that
of saline-treated mice (p < 0.0001, Figure 3C). Though
not significant, a slight increase in the Cho/Cr to peak was
seen in the Dox+MESNA group compared to Dox alone

Figure 2: Behavior testing for male B6C3 mice treated with saline, MESNA, Dox (25 mg/kg), or Dox+MESNA. MESNA
was administered at 160 mg/kg i.p. 15 min before DOX/ Saline as well as 3 h and 6 h after Dox/Saline. Brain and plasma samples were
acquired post 72 h treatments. N = 7–8 per treatment group. (A) Novel Object Recognition (NOR) testing provides a measure of cognitive
function through recognition memory. Dox group performed at a significantly lower RI than Saline, MESNA and Dox+MESNA groups
at 72 h post treatment (*P < 0.05). MESNA given with Dox rescued this measure of cognitive function. (B) Open Field Testing was used
to provide a comparison of average total locomotor activity among groups. Dox group is significantly different from MESNA control
group at 24 h post treatment. Both the Dox and Dox+MESNA groups showed significantly decreased average total movement compared
to Saline group or MESNA group at 72 h post treatment (*P < 0.05). Comparisons to MESNA group at 72 h were not shown in the figure.
The result shows that motor activity in an open field declines following Dox treatment, and this motor dysfunction is not ameliorated by
MESNA treatment.
www.oncotarget.com

30327

Oncotarget

(Figure 3D). This result suggests that MESNA may be
protecting cognition by a different mechanism in addition
to partial restoration of the Cho/Cr ratio. As noted above,
phosphocholine and glycerophosphorylcholine are the
major contributors to the Cho peak, while choline itself is
a smaller contributor.

the treatment regimen with Dox did not prevent the Doxrelated decrease in PLD activity.

DISCUSSION
Based on our earlier studies, we previously
proposed the following model for CICI [47]: Plasma
protein oxidation, including that of ApoA-I, induced by
the redox cycling of Dox, leads to elevation of TNF-α
in the periphery. TNF-α crosses the BBB by receptormediated endocytosis to induce microglial activation,
leading to further TNF-α release, increased production
of NO, mitochondrial dysfunction, neuronal death, and
consequent cognitive impairment [4, 10, 11, 24–26, 28].
We previously showed that oxidative damage occurs early
in neurodegenerative processes [48–52]. Nearly half of
FDA approved anti-cancer drugs result in elevation of
ROS and induce oxidative stress [23]. A large percentage
of cancer survivors suffer from CICI, now widely
recognized as a chemotherapy complication [1–5]. The
goals of this study were to gain insights into mechanisms
of CICI and its potential prevention, with the long-term
goal to progress toward prevention or at least successful
management of CICI and an improved quality of life
for an ever-growing number of cancer survivors. Figure
5 depicts major changes in brain following treatment of
mice with non-BBB permeable Dox and modulation or
amelioration of these changes by MESNA.

Dox administration results in decreased PC-PLC
and PLD activity
To gain insight into a possible mechanism for the
MRS-indexed changes in choline-containing compounds,
the activities of phospholipase enzymes known to act on
PtdCho, a major source of choline and PCho in the brain
were tested. PC-PLC cleaves PtdCho at the glycerolphosphate bond producing the second messenger,
diacylglycerol (DAG), and PCho. Phospholipase D (PLD),
located in the plasma membrane, cleaves the headgroup
from phospholipids thereby releasing soluble choline
from PtdCho into the cytosol leaving phosphatidic acid.
Activity of both PC-PLC and PLD in brain were severely
impaired at 72 h following Dox administration (p <
0.01 and p < 0.01, respectively; Figure 4) providing a
possible explanation for the dramatic decrease seen in the
choline-containing peaks (as measured by MRS Cho/Cr
ratio). MESNA, co-administered with Dox, completely
rescued PC-PLC activity back to the activity observed
in the saline-treated group. However, adding MESNA to

Figure 3: (A) H1-MRS uses proton signatures from hydrogen in much the same way as NMR to create two-dimensional images of the

tissue (right) and a spectrum of peaks reflecting a neurochemical profile of one mouse after 72 h treatment that includes NAA, Cho, Cr, and
others (left). (B) Bilateral H1-MRS scans of mouse hippocampus revealed that Dox treatment lead to a slight but statistically significant
decrease compared to Saline group (*P < 0.05) in the NAA/Cr ratio. (C) A six standard deviation decrease in the Cho/Cr ratio in the Doxtreated group compared to saline control (***P < 0.001). (D) Co-administration of MESNA with Dox resulted in a trend toward rebound in
Cho/Cr compared to Dox alone. Greater variability was seen in Cho/Cr in the Dox+MESNA group.
www.oncotarget.com
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Direct toxic effects caused by the chemotherapy
drugs lead to damage to biomolecules including lipids,
proteins, lipoproteins, and genetic material [10, 11, 23,
53–55]. Oxidative stress caused by anticancer drugs leads
to damage to biomolecules in non-targeted, non-cancerous
tissues including the blood, heart, and brain [23, 47].
Reactive oxygen and reactive nitrogen species (ROS,
RNS) include such species as superoxide radical anion
(O2-•), nitric oxide (NO), peroxynitrite (ONOO-), and
hydroxyl radical (HO•). Some of these have both functions
essential to life and effects damaging to biomolecules
necessary for life. O2-• is produced by inefficient reduction
of molecular oxygen in the mitochondria [23, 56–58]. NO,
a free radical, is produced from L-arginine by catalysis
of various forms of the enzyme, nitric oxide synthase.
Together, O2-• and NO combine to form another reactive
species, ONOO- [59, 60]. Hydrogen peroxide (H2O2),
produced through the actions of superoxide dismutase
(SOD) [61, 62], is converted to water and molecular
oxygen by peroxidases, but H2O2 can result in production
of HO• in the presence of iron(II) or copper(I) ions
via Fenton Chemistry [63–65]. These radical species
can cause the formation of carbon-centered radicals,
alkoxyl radicals, and peroxyl radicals further damaging
biomolecules through a free radical chain reaction [66,
67]. In particular, this type of oxidative stress can lead to
lipid peroxidation in the lipid bilayer and the formation
of reactive alkenals such as HNE, a lipid peroxidation
product easily formed in brain containing abundant
arachidonic acid. HNE can covalently bind proteins by
Michael addition to alter protein structure and function

[68–71]. The brain is particularly vulnerable to oxidative
damage due to relatively low antioxidant defenses,
high oxygen consumption, and high concentrations of
polyunsaturated fatty acids.
Administration of the prototypical ROS-generating
anti-cancer drug, Dox, leads to oxidative damage to
plasma proteins through both direct and indirect toxicity
independent of its cancer killing ability. Dox directly
continually causes oxidative stress in peripheral tissues
by redox cycling of the quinone moiety in its structure
[72]. Dox-induced cardiac dysfunction, in part is due to
mitochondrial damage, is well established and is used as
a dose limiting criteria in treatment protocols [73–76].
Indirectly, Dox elevates levels of TNF-α in the plasma
and, subsequently, the brain leading to neuronal death [10,
24]. Macrophages are the principal cell source of TNF-α;
however, cellular targets and biological effects are varied
including inflammation, neutrophil activation, catabolism
in fat and muscle, triggering the synthesis of acute-phase
proteins, and apoptosis in many cell types. Such responses
can be beneficial if acute but quite harmful if chronic or
sustained.
Under normal conditions, ApoA-I suppresses TNF-α
release in plasma [34, 77]. Once oxidized, ApoA-I loses
this ability and may actually exacerbate TNF-α release
[10, 32]. The oxidative status of ApoA-I is crucial to its
role in TNF-α suppression. Dox-induced ApoA-I oxidation
and TNF-α increase is suppressed by co-administration of
MESNA [10]. MESNA is rapidly oxidized, scavenging
reactive species in circulation. MESNA’s time in
circulation is short-lived as it is rapidly renally eliminated,

Figure 4: Phosphatidylcholine-specific phospholipase C (PC-PLC) and Phospholipase D (PLD) activity in brain
72 h post-treatment presented as percent saline control. (A) PC-PLC activity at 22.5 h of incubation, the peak fluorescence of

the corresponding positive control in these trials, at room temperature in the dark. Cleavage of the assay substrate by PC-PLC yields a
dye-labeled diacylglycerol (DAG) which fluoresces using an excitation and emission maxima of 509 nm and 516 nm, respectively. Dox
administration caused a significant decrease in PC-PLC activity compared to saline treated mice (**p < 0.01). Co-administration of MESNA
rescued decreased PC-PLC activity by Dox (**p < 0.01). (B) PLD activity at 1h of incubation, the peak fluorescence of the corresponding
positive control in these trials, at 37° C protected from light. PLD cleaves the headgroup from phospholipids thereby releasing the choline
from PtdCho. Assay reactions involving the choline produce a product that fluoresces using an excitation and emission maxima of 571 and
585 nm, respectively. Dox treatment resulted in significantly decreased PLD activity compared to saline treated controls (**p < 0.01). PLD
activity in the Dox+MESNA group was not significantly different from the group receiving Dox alone.
www.oncotarget.com

30329

Oncotarget

thereby reducing the chance for potential unwanted side
effects [78].
Oxidative stress data presented here support the
results of our previous studies. Dox administration leads
to oxidative stress in both plasma and brain as evidenced
by increased protein carbonyl and protein-bound HNE.
Both of these damages are prevented when MESNA is
administered just prior to Dox. These results, shown for
the first time in brain, confirm our prior results in plasma.
Cognitive testing of saline, Dox, MESNA, and
Dox+MESNA treatment groups revealed memory
impairment in animals receiving Dox alone. Cognitive
performance, as measured by NOR, was rescued in the
group that received MESNA with Dox at 72 h posttreatment. Open field testing was employed as a gauge of
locomotor activity. The treatment groups receiving Dox
displayed less total movement than those without Dox
treatment. This finding is consistent with prior studies of
others [79, 80] that conceivably could be due to protein
oxidation of muscles and/ or the effects of elevated
levels of the pro-inflamatory cytokine TNF-α [81, 82].
Dox-induced motor dysfunction is not ameliorated by
MESNA treatment. However, the Dox and Dox+MESNA
treatment groups displayed similar total movement in the
test environment decreasing potential confounds when
comparing NOR performance between these two groups.
Total object exploration time was similar among all
treatment groups and decreased with repeated exposure to
the environment. After only 24 h post-injection, animals
in the Dox-treated group were already showing a trend
of decreased preference for the novel object compared to

the other treatment groups. By day three, the Dox treated
animals on average displayed no preference for the novel
object over the familiar one. This is compelling evidence
for Dox-induced cognitive impairment. MESNA rescued
much of this Dox-induced cognitive deficit (Figure 2A),
which we speculate is due to prevention of oxidative stress
in brain following Dox treatment (Figure 1).
H1-MRS of hippocampus of similarly treated
animals revealed changes in the neurochemical profile
in Dox-treated group versus saline control. A slight but
significant decline in the NAA/Cr ratio was observed in the
Dox group suggesting neuronal damage. More profoundly,
MRS revealed, on average, a large six standard deviation
decline in the Cho/Cr ratio in the hippocampus of the Doxtreated group compared to the saline-treated group. These
results are consistent with results from another study in
which Ciszkowska-Łysoń et al. observed a time-related
decrease in the Cho/Cr ratio following chemotherapy
which they attributed to potential myelin damage [83].
Three days after Dox treatment may be too soon to see
measurable myelin damage in brain detectable by MRS.
Changes in choline-containing compounds on MRS
are thought to be associated with membrane turnover
(phospholipid synthesis and degradation) [84, 85].
Choline levels have been shown to be proportional to cell
density [86] and to correlate with degree of malignancy
in cancers [84, 85]. A decrease in the Cho peaks in brain
also has been seen in brain aging as well as a decrease
in choline uptake in older adults [85, 87, 88]. A decrease
in the Cho/Cr ratio is indicative of decreased cell
density and necrosis [85, 86]. Upon Dox administration,

Figure 5: A pictorial summary of results of Dox-induced elevated oxidative stress and neurochemical alterations in the
periphery and brain as well as cognitive decline (left) and MESNA-mediated protection against these Dox-facilitated
effects in both plasma and brain.
www.oncotarget.com
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the decreased PCho and/or choline is consistent with
changes in the production or metabolism of PtdCho or
the neurotransmitter, acetylcholine (ACh) [89, 90]. Due
to the widespread functions of ACh in both the motor
and somatic divisions of the autonomic nervous system,
the effects of chemotherapy-induced changes to this
neurotransmitter may be varied and dramatic and need to
be further explored. Evidence exists that ACh-associated
memory, intelligence, and mood may, in part, be mediated
by choline levels and ACh metabolism in the brain [91].
As noted, the decrease in the Cho peak in brain
revealed by MRS spectra of Dox-treated mice may be due
to decreased membrane synthesis, decreased myelination,
and potentially cell loss. Such observed changes by MRS
conceivably may be consistent with white matter changes
seen in human breast cancer patients [92–95]. Magnetic
resonance imaging (MRI) and magnetic resonance
spectroscopy (MRS) are proving to be useful tools both for
visualization of white matter changes and changes in the
neurochemical profile indicative of axonal degeneration
and demyelination in the brains of living subjects
following chemotherapy [95]. Indeed, the integrity of

lipid-rich myelin covered white matter have been shown
to be altered as well as damage to gray matter with
associated functional deficits following systemic cancer
chemotherapy, in some cases years after chemotherapy [8,
95, 96]. Studies have shown that chemotherapy-induced
neuroinflammation, including increases in TNF-α, are
correlated with changes in myelination and cognitive
impairment [96]. Coupled with neuropsychological
tests, neuroimaging techniques can provide important
information to help outline a mechanism for clinical
and biochemical changes in the brain that results from
chemotherapy and help researchers and clinicians work
together to decrease or prevent unnecessary cognitive
decline in cancer patients [97–99].
Elevated TNF-α is reported to decrease synthesis of
PtdCho [90, 100]. We previously hypothesized that TNF-α
elevated in the periphery and in brain following cancer
chemotherapy plays a central role in CICI [4, 10, 24, 26,
39, 47, 101]. PtdCho is also the principal phospholipid
found in high-density lipoprotein (HDL), teaming with
ApoA-I in cholesterol transport, one of the most common
constituents found in biological membranes. PtdCho is

Figure 6: Proposed model of mechanism of CICI. ROS-associated chemotherapeutic agent Dox causes elevation of oxidative stress

including protein-bound HNE. ApoA1 is oxidized by protein-bound HNE with conformational and further functional changes. ApoA1 thus
loses its ability to interact with ABCA1, increasing TNF-α in the periphery as a consequence. TNF-α can then cross blood brain barrier by
endocytosis of TNFR1, activate microglia in brain to make more local TNF-α, leading to neuronal mitochondrial dysfunction, apoptosis and
subsequent cognitive decline. MESNA can block the ROS in periphery (plasma) and ameliorate oxidative stress and cognitive impairment
in brain (labeled with green arrows in the Figure 6.)
www.oncotarget.com
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usually located in the outer bilayer leaflet with the choline
head group exposed to the aqueous cytosolic environment
playing vital roles in membrane-mediated cell signaling.
The turnover of PtdCho is reportedly accelerated
in models of mitochondrial dysfunction mimicking
Alzheimer disease (AD) patterns of metabolic changes
in the brain [102]. Cleavage of PtdCho by PC-PLC
yields PCho and the second messenger DAG, whereas
cleavage of PLD releases choline used in the synthesis
of the neurotransmitter, ACh. PC-PLC plays vital roles in
several cell signaling pathways involved in both apoptosis
and cell survival and in a variety of disease processes.
Hence, decreased DAG could severely impair normal
cell signaling and be important for CICI. Dox-treatment
severely impaired the activity of both PC-PLD and PLD
in brain of the mouse model of chemotherapy used in this
study (Figure 4). The decrease in activity of these two
enzymes may, in part, explain the changes in the Cho
signal seen on hippocampal H1-MRS. The slight though
not statistically significant recovery of the Cho peaks
when MESNA was co-administered with Dox may be
due to protection of PC-PLC function by MESNA but no

protection of PLD. Therefore, more studies are warranted
to further elucidate this mechanism.
Based on previous work by our group and the
results of the current study, we propose the following
expanded model in Figure 6 for CICI augmenting that
published by our group previously [10]. ROS-associated
chemotherapeutic agents cause oxidative damage to
plasma proteins, including ApoA-I, and lead to peripheral
elevation of the inflammatory cytokine, TNF-α [10,
24]. Unaltered ApoA-I interacts with the ATP-binding
membrane cassette transporter A1 (ABCA1) involved in
cholesterol transport [35, 77]. Given that protein structure
changes when oxidized [103], the initial interaction of
ApoA-I with ABCA1 is altered when ApoA-I is oxidized.
Hence, TNF-α would be elevated in plasma. Elevated
TNF-α crosses the BBB leading to microglial activation,
increased ROS and further TNF-α release in the brain,
leading to mitochondrial dysfunction and subsequent
cognitive decline [4, 11]. MESNA can protect both plasma
and brain from oxidative stress including protein carbonyl
and protein-bound HNE. MESNA also can save memory
function and PC-PLC activity in brain following Dox

Figure 7: A pathway to apoptosis following Dox treatment. Elevated TNF-α inhibits biosynthesis of PtdCho, which coupled
to decreased activity of PC-PLC, leads to decreased PCho. Decreased PCho results in a relative increased ceramide due to decreased
conversion to sphingomyelin. Increased ceramide leads to apoptosis.
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administration. TNF-α inhibition of PtdCho synthesis
may result in decreased PCho availability. Since ceramide
couples with PCho to produce sphingomyelin [104],
decreased PCho would lead to elevated ceramide. The
latter is a known inducer of apoptosis [105–108], and we
previously showed elevated apoptosis in brain of Doxtreated mice [25] (Figure 7). Dox-induced decreased PCPLC and PLD activities may result in dysregulation of cell
survival and apoptosis pathways that involve PC-PLC.
CICI severely impacts the quality of life of cancer
survivors. This paper shows for the first time strong
evidence that elevated brain oxidative damage following
Dox administration leads to cognitive decline, and both
are prevented by MESNA. These studies form the basis of
additional investigations to gain insights into CICI.

scanned 72 h post treatment, because Dox has been shown
to cause maximal protein oxidation and lipid peroxidation
72 h post treatment [11]. Following MRS or novel
object recognition (NOR) studies, these animals were
euthanized and blood and tissues collected for molecular
or biochemical analysis.

Cognitive function testing: Novel object
recognition and open field testing
Cognitive performance was evaluated using a NOR
paradigm [111, 112]. One day prior to treatment, each
mouse was acclimated for 1 h to an empty, Plexiglas cage
which was dedicated to this mouse for all trials. Several
hours after acclimation, the mouse was returned to the
cage containing two identical objects (object A) placed at
opposite corners, and the time spent exploring each object
was recorded. A mouse was considered to be exploring
when it pointed its nose toward the object at a distance of
2 cm or less. Throughout the protocol, trial duration was
5 min unless total exploration time was less than 10 s. In
this case, the trial was extended to ensure a minimum of
10 s of exploration. On the day of treatment, mice were
re-introduced to the two “familiar” objects (object A)
in the morning and, 4 h later, baseline memory function
was evaluated by replacing one of the familiar objects
with a novel object (object B). Immediately following the
baseline memory trial, mice received an injection. One
day after injection, the mice were exposed to the original
two (familiar) objects (object A) and, after a 4 h interval,
one of the familiar objects was replaced with a novel object
(object C). At 3 days after treatment, memory was tested
again (novel object D paired with familiar object A). Data
are reported as a recognition index, which was calculated
time spent exploring the novel object as the percentage
of total exploration time. All trials were performed by an
investigator blinded to treatment conditions.
At 1 and 3 days after treatment, motor activity was
tested using an Open Field test [113]. Mice were placed
in a 48 × 33 cm empty Plexiglas box and videotaped
from above for a 5 minute trial (EZVideoDV version
5.51). Trials were performed by an investigator blinded
to treatment conditions.

MATERIALS AND METHODS
Chemicals
Precision Plus Protein™ All Blue Standards, BCA
reagents, and nitrocellulose membranes were purchased
from Bio-RAD (Hercules, CA, USA). EnzChek®
Direct Phospolipase C Assay Kit and Amplex® Red
Phospholipase D Assay Kit were purchased from
Invitrogen/Life Technologies (Carlsbad, CA). Chemicals,
proteases, protease inhibitors, and antibodies used in this
study were purchased from Sigma-Aldrich (St. Louis, MO,
USA) unless otherwise noted.

Statistical analysis
All data are presented as mean ± SEM, and statistical
analyses were performed using ANOVA followed by a
two-tailed Student's t-test to make individual comparisons
where relevant, with p < 0.05 considered significant. The
D’Agostino & Pearson omnibus normality test was used
where appropriate.

Animals
Mice used in this study were the F1 progeny of
C57BL/6 x C3H hybrids (B6C3) purchased from the
Jackson Laboratory. Male B6C3 mice (2–3 months old),
each weighing approximately 30 grams were kept under
standard conditions housed in the University of Kentucky
Animal Facility, and all experimental procedures were
approved by the Institutional Animal Care and Use
Committee of the University of Kentucky. Doxorubicin
HCl was purchased from Bedford Laboratories™,
and MESNA was purchased from Baxter Healthcare
Corporation. Mice were injected using a single
intraperitoneal (i.p.) dose of 25 mg/kg Dox or the same
volume of saline as a control [109, 110]. MESNA was
administered at 160 mg/kg i.p. 15 min before DOX as well
as 3 h and 6 h after Dox. Animals tested using MRS were
www.oncotarget.com

Hydrogen magnetic resonance imaging
spectroscopy
H1-MRS (hydrogen magnetic resonance imaging
spectroscopy) was used to quantify neurochemical changes
in the mouse hippocampus. MRS data were acquired on a
7 T BrukerClinscan horizontal bore system (7.0 T, 30 cm,
300 Hz) equipped with a triple-axis gradient system
(630 mT/m and 6300 T/m/s). A closed cycle, 14 K
quadrature cryocoil allowed for a 2.8 signal to noise
increase relative to standard coils.
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Phospholipase C and Phospholipase D Activity
Assays

The mice were anesthetized with 1.3 % percent
isoflorane using MRI compatible CWE Inc. equipment.
Mice were held in place on a Bruker scanning bed with
a tooth bar, ear bars and tape. Body temperature and
respiration rate were monitored using equipment from SA
Instruments Inc. The animals were maintained at 37° C
with a water heating system built into the scanning bed. T2
weighted turbo spin echo sequences (TE 40ms, TR 2890ms,
Turbo 7, FOV 20mm, 0.156 × 0.156 × 5.0 mm3) were
acquired and used for the placement of the spectroscopy
voxel. The scanning procedure took 40 min. A 2 × 5.5 ×
3 mm3 PRESS spectroscopic voxels (TE 135 ms, TR 1500 ms,
400 avg, CHESS water suppression) was placed to cover
both hippocampi. Spectrum analysis was performed using
jMRUI [114] to quantify the area under 10 peaks in the
spectrum. The creatine peak was used to normalize the
peak of choline-containing compounds (Cho), primarily
phosphocholine and glycerophosphorylcholine.

Phosphatidylcholine-specific phospholipase C (PCPLC) and phospholipase D (PLD) activity assays were
performed using manufacturers’ instructions provided
with the EnzChek® Direct Phospolipase C Assay Kit and
Amplex® Red Phospholipase D Assay Kit by Invitrogen/
Life Technologies (Carlsbad, CA), respectively.
Fluorescence intensity for each assay was measured using
a SPECTRAFluor Plus instrument and quantified using
associated Magellan™ software by TECAN over a period
of 24 h with the kinetic peaks of the positive controls used
for comparison.

Abbreviations
CICI: Chemotherapy-induced cognitive impairment;
Dox: Doxorubicin; MESNA: 2-mercaptoethanesulfonate
sodium; MRS: magnetic resonance spectroscopy; MRI:
magnetic resonance imaging; PLC: phospholipase C;
PLD: phospholipase D; PtdCho: phosphatidylcholine;
PC-PLC: phosphatidylcholine-specific phospholipase C;
NOR: novel object recognition; TNF-α: tumor necrosis
factor alpha; TNFR1: TNF-α receptor 1; HNE: 4-hydroxy2-transnonenal; BSA: bovine serum albumin; BCA:
bicinchoninic acid; BCIP: 5-bromo-4-chloro-3-indolylphosphate dipotassium; NBT: nitro blue tetrazolium
chloride; ALP: alkaline phosphatase; BBB: blood-brain
barrier; ROS: reactive oxygen species; RNS: reactive
nitrogen species; O2-•: superoxide radical anion; NO:
nitric oxide; ONOO-: peroxynitrite; HO•:hydroxyl radical;
H2O2: hydrogen peroxide; SOD: superoxide dismutase;
AD: Alzheimer’s Disease; RI: recognition index; NAA:
N-acetylaspartate; Cho: choline-containing compounds;
Cr: creatine; PCho: phosphocholine; DAG: diacylglycerol;
ACh: acetylcholine.

Sample preparation
Protein estimation was performed using the
bicinchoninic acid (BCA, Pierce) assay
Homogenized whole brain and plasma samples
were diluted according to initial protein estimation results
using 20 ug sample in isolation buffer [0.32 M sucrose,
2 mM EDTA, 2mM EGTA, and 20 mM HEPES pH 7.4
with protease inhibitors, 0.2 mM PMSF, 20 ug/mL trypsin
inhibitor, 4 μg/ml leupeptin, 4 μg/ml pepstatin A, and
5 μg/ml aprotinin].

Slot blot assay
The slot-blot method was used to determine levels
of protein carbonyls and protein-bound 4-hydroxynonenal
(HNE) in brain. For protein carbonyl determination,
samples were derivatized with 2,4-dinitrophenylhydrazine
(DNPH). For HNE, samples were solubilized in Laemmli
buffer. Protein (250 ng) from each sample was loaded
onto a nitrocellulose membrane inrespective wells in a
slot-blot apparatus (Bio-Rad) under vacuum. Membranes
were blocked in 3% bovine serum albumin (BSA) in PBS
with 0.2% (v/v) Tween-20 for 1.5 h and then incubatedin
primary antibody (anti-dinitrophenylhydrazone primary
or anti-protein-bound HNE, respectively, each produced
in rabbit, Sigma-Aldrich) for 2 h, washed three times in
PBS with 0.2% (v/v) Tween-20 and then incubated for
1 h with secondary antibody (goat anti-rabbit secondary
linked to alkaline phosphatase). Membranes were
developed with 5-bromo-4-chloro-3-indolyl-phosphate
(BCIP) dipotassium and nitro blue tetrazolium (NBT)
chloride in alkaline phosphatase activity (ALP) buffer,
dried, and scanned for analysis. Image analysis was
performed using Scion Image (Scion Corporation,
Frederick, MD).
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